TFF Pharmaceuticals (TFFP) shares tumbled 72% in premarket activity Friday a day after the board approved the company's dissolution and liquidation.
The company plans to call a special stockholders' meeting to seek approval of the dissolution plan, according to a filing with the US Securities and Exchange Commission.
TFF said it has terminated its employees in connection with the planned wind down of its operations.
The company also said Chief Executive Harlan Weisman, Chief Financial Officer Kirk Coleman and Chief Medical Officer Zamaneh Mikhak have stepped down from their respective positions as of Nov. 14. TFF Pharmaceuticals said its board named Craig Jalbert as chief executive, president and chief financial officer.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。